Varian, Inc. Reports Higher Sales and Profits for the Second Quarter of Fiscal Year 2004
Varian, Inc. reported higher sales of $232.7 million for the second quarter of fiscal year 2004, representing an increase of 13.7% over second quarter 2003 sales of $204.6 million. The increase was driven by the general economic improvement and by strong demand for the Company's newer products. All three of the Company's segments, particularly the vacuum Technologies segment, contributed to the revenue growth.
Pro forma net earnings were $15.4 million for the second quarter of fiscal year 2004, or $0.43 pro forma diluted earnings per share, compared to $14.3 million, or $0.41 pro forma diluted earnings per share, in the second quarter of fiscal year 2003. On a GAAP basis, net earnings in the second quarter of fiscal year 2004 were $14.7 million, or $0.41 diluted earnings per share, compared to $13.9 million, or $0.40 diluted earnings per share, in the second quarter of fiscal year 2003.
Results by Segment
Scientific Instruments revenues for the second quarter of fiscal year 2004 were $149.9 million, representing a 10.6% increase over revenues of $135.5 million in the second quarter of the prior year. Demand was strong in Europe and continued to improve in North America.
Scientific Instruments operating profit margin for the second quarter of fiscal year 2004 was 10.2% on a pro forma basis and 9.5% on a GAAP basis. As the Company had anticipated, pro forma operating margins were lower versus the year-ago quarter, but improved slightly sequentially. Operating margins continued to be adversely affected by a mix shift towards high-field nuclear magnetic resonance (NMR) systems and leading edge cold probes for NMR and away from lower field NMR systems. The negative impact of this mix shift on operating margins was partially offset by stronger sales of higher margin mass spectrometry products and application-based consumables.
Vacuum Technologies revenues of $38.4 million rose 36.5% in the second quarter of fiscal year 2004 compared to revenues of $28.2 million in the second quarter of fiscal year 2003. Vacuum Technologies operating profit margin in the second quarter of fiscal year 2004 was 17.6% on both a pro forma and GAAP basis. During the quarter, Vacuum Technologies revenue growth was fueled by significantly higher demand in both life science and industrial applications. In life sciences, the segment experienced a substantial uptick in demand for turbomolecular pumps for use in OEM mass spectrometers. Industrial growth was driven by semiconductor applications, but demand for pumps for broad industrial uses also increased during the quarter. Operating margins improved primarily as a result of sales volume leverage.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents
Seeing a diagnosis: How an eye test could aid Alzheimer's detection
C-mo Medical Solutions raises €4.1 million aiming to transform cough monitoring
New technique for testing drugs to treat cystic fibrosis and epilepsy
Neuronal Parkinson inclusions are different than expected - Study raises new questions about the etiology of Parkinson’s disease
Analytik Jena Sells Site in Eisfeld - New investor acquiring entire Optics business unit as well as component production for analytical technology
Toxic agents behind Parkinson's disease seen at work for the first time - First look at how toxic protein clusters disrupt the membranes of healthy brain cells.
Ocean Optics Employee Wins Global Technology Award - Nelson Chandler takes £20K top prize from multi-national technology company
Measuring the magnetism of antimatter - Researchers measure antiprotons more accurately than ever before
KRÜSS is one of the innovation leaders in 2018 - TOP 100 competition success
COVID-19 : Measuring viral RNA to predict which patients will die - A statistical model uses a blood biomarker of SARS-CoV-2 to identify infected patients who are most at risk of dying of COVID-19
